Key result
Conditional deletion of Gαs in the SA node induced bradycardia, which preserved ejection fraction and attenuated pathological cardiac hypertrophy following myocardial infarction.
Why the study?
The study aimed to determine the pathophysiological impact of heart rate slowing on cardiac function.
Does selective heart rate reduction via Gαs deletion in the sinoatrial node protect against pathological cardiac hypertrophy in murine models?
Does selective heart rate reduction via Gαs deletion in the sinoatrial node protect against pathological cardiac hypertrophy in murine models?
This genetic murine model demonstrates that pure heart rate reduction protects against pathological cardiac hypertrophy, supporting its therapeutic role in heart failure independent of pharmacological pleiotropic effects.
Answers are grounded in this paper and cite their sources.
Pure HR reduction may protect against post-MI hypertrophy in mice; hypothesis-generating for human HF, with no practice change warranted.
We aimed to determine the pathophysiological impact of heart rate (HR) slowing on cardiac function. We have recently developed a murine model in which it is possible to conditionally delete the stimulatory heterotrimeric G-protein (Gαs) in the sinoatrial (SA) node after the addition of tamoxifen using cre-loxP technology. The addition of tamoxifen leads to bradycardia. We used this approach to examine the physiological and pathophysiological effects of HR slowing. We first looked at the impact on exercise performance by running the mice on a treadmill. After the addition of tamoxifen, mice with conditional deletion of Gαs in the SA node ran a shorter distance at a slower speed. Littermate controls preserved their exercise capacity after tamoxifen. Results consistent with impaired cardiac capacity in the mutants were also obtained with a dobutamine echocardiographic stress test. We then examined if HR reduction influenced pathological cardiac hypertrophy using two models: ligation of the left anterior descending coronary artery for myocardial infarction and abdominal aortic banding for hypertensive heart disease. In littermate controls, both procedures resulted in cardiac hypertrophy. However, induction of HR reduction prior to surgical intervention significantly ameliorated the hypertrophy. In order to assess potential protein kinase pathways that may be activated in the left ventricle by relative bradycardia, we used a phospho-antibody array and this revealed selective activation of phosphoinositide-3 kinase. In conclusion, HR reduction protects against pathological cardiac hypertrophy but limits physiological exercise capacity.
No takes yet. Share an insight, caveat, or question.
Sebastian et al. (2022) studied Pathological cardiac hypertrophy and myocardial infarction (n=116). Conditional deletion of Gαs in the SA node (tamoxifen-induced bradycardia) vs. Littermate controls treated with tamoxifen was evaluated on Left ventricular ejection fraction 2 weeks post-myocardial infarction (p=<0.001). Conditional deletion of Gαs in the SA node induced bradycardia, which preserved ejection fraction and attenuated pathological cardiac hypertrophy following myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: